Model-based PEEP titration versus standard practice in mechanical ventilation: a randomised controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
01 Feb 2020
Historique:
received: 08 09 2019
accepted: 29 12 2019
entrez: 3 2 2020
pubmed: 3 2 2020
medline: 20 11 2020
Statut: epublish

Résumé

Positive end-expiratory pressure (PEEP) at minimum respiratory elastance during mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS) may improve patient care and outcome. The Clinical utilisation of respiratory elastance (CURE) trial is a two-arm, randomised controlled trial (RCT) investigating the performance of PEEP selected at an objective, model-based minimal respiratory system elastance in patients with ARDS. The CURE RCT compares two groups of patients requiring invasive MV with a partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 200; one criterion of the Berlin consensus definition of moderate (≤ 200) or severe (≤ 100) ARDS. All patients are ventilated using pressure controlled (bi-level) ventilation with tidal volume = 6-8 ml/kg. Patients randomised to the control group will have PEEP selected per standard practice (SPV). Patients randomised to the intervention will have PEEP selected based on a minimal elastance using a model-based computerised method. The CURE RCT is a single-centre trial in the intensive care unit (ICU) of Christchurch hospital, New Zealand, with a target sample size of 320 patients over a maximum of 3 years. The primary outcome is the area under the curve (AUC) ratio of arterial blood oxygenation to the fraction of inspired oxygen over time. Secondary outcomes include length of time of MV, ventilator-free days (VFD) up to 28 days, ICU and hospital length of stay, AUC of oxygen saturation (SpO The CURE RCT is the first trial comparing significant clinical outcomes in patients with ARDS in whom PEEP is selected at minimum elastance using an objective model-based method able to quantify and consider both inter-patient and intra-patient variability. CURE aims to demonstrate the hypothesized benefit of patient-specific PEEP and attest to the significance of real-time monitoring and decision-support for MV in the critical care environment. Australian New Zealand Clinical Trial Registry, ACTRN12614001069640. Registered on 22 September 2014. (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366838&isReview=true) The CURE RCT clinical protocol and data usage has been granted by the New Zealand South Regional Ethics Committee (Reference number: 14/STH/132).

Sections du résumé

BACKGROUND BACKGROUND
Positive end-expiratory pressure (PEEP) at minimum respiratory elastance during mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS) may improve patient care and outcome. The Clinical utilisation of respiratory elastance (CURE) trial is a two-arm, randomised controlled trial (RCT) investigating the performance of PEEP selected at an objective, model-based minimal respiratory system elastance in patients with ARDS.
METHODS AND DESIGN METHODS
The CURE RCT compares two groups of patients requiring invasive MV with a partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 200; one criterion of the Berlin consensus definition of moderate (≤ 200) or severe (≤ 100) ARDS. All patients are ventilated using pressure controlled (bi-level) ventilation with tidal volume = 6-8 ml/kg. Patients randomised to the control group will have PEEP selected per standard practice (SPV). Patients randomised to the intervention will have PEEP selected based on a minimal elastance using a model-based computerised method. The CURE RCT is a single-centre trial in the intensive care unit (ICU) of Christchurch hospital, New Zealand, with a target sample size of 320 patients over a maximum of 3 years. The primary outcome is the area under the curve (AUC) ratio of arterial blood oxygenation to the fraction of inspired oxygen over time. Secondary outcomes include length of time of MV, ventilator-free days (VFD) up to 28 days, ICU and hospital length of stay, AUC of oxygen saturation (SpO
DISCUSSION CONCLUSIONS
The CURE RCT is the first trial comparing significant clinical outcomes in patients with ARDS in whom PEEP is selected at minimum elastance using an objective model-based method able to quantify and consider both inter-patient and intra-patient variability. CURE aims to demonstrate the hypothesized benefit of patient-specific PEEP and attest to the significance of real-time monitoring and decision-support for MV in the critical care environment.
TRIAL REGISTRATION BACKGROUND
Australian New Zealand Clinical Trial Registry, ACTRN12614001069640. Registered on 22 September 2014. (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366838&isReview=true) The CURE RCT clinical protocol and data usage has been granted by the New Zealand South Regional Ethics Committee (Reference number: 14/STH/132).

Identifiants

pubmed: 32007099
doi: 10.1186/s13063-019-4035-7
pii: 10.1186/s13063-019-4035-7
pmc: PMC6995650
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

130

Subventions

Organisme : Health Research Council of New Zealand
ID : 13/213

Références

Respir Med. 2009 Aug;103(8):1174-81
pubmed: 19269800
JAMA. 2010 Mar 3;303(9):865-73
pubmed: 20197533
JAMA. 2008 Feb 13;299(6):646-55
pubmed: 18270353
Math Biosci. 2017 Feb;284:21-31
pubmed: 27301378
Intensive Care Med. 2017 Feb;43(2):250-252
pubmed: 28074228
Chest. 2007 Mar;131(3):921-929
pubmed: 17356115
PLoS One. 2015 Jan 22;10(1):e0114847
pubmed: 25611069
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1156-63
pubmed: 18776154
Crit Care. 2013 Mar 25;17(2):R54
pubmed: 23531269
Am J Respir Crit Care Med. 2006 Aug 1;174(3):268-78
pubmed: 16690982
Biomed Eng Online. 2011 Dec 23;10:111
pubmed: 22196749
Curr Opin Crit Care. 2007 Feb;13(1):64-72
pubmed: 17198051
N Engl J Med. 1998 Feb 5;338(6):347-54
pubmed: 9449727
Intensive Care Med. 1990;16(6):372-7
pubmed: 2246418
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Crit Care. 2012 Jan 08;16(1):R4
pubmed: 22226331
N Engl J Med. 2004 Jul 22;351(4):327-36
pubmed: 15269312
J Crit Care. 2009 Mar;24(1):74-80
pubmed: 19272542
Anaesth Intensive Care. 2009 Jan;37(1):99-107
pubmed: 19157354
Intensive Care Med. 2003 Nov;29(11):1936-42
pubmed: 12955187
Crit Care Med. 2007 Jan;35(1):214-21
pubmed: 17110872
Am Rev Respir Dis. 1988 Sep;138(3):720-3
pubmed: 3202424
Pilot Feasibility Stud. 2015 Mar 21;1:9
pubmed: 28435689
Biomed Eng Online. 2014 Sep 30;13:140
pubmed: 25270094
Curr Opin Crit Care. 2010 Feb;16(1):39-44
pubmed: 19996966
Minerva Anestesiol. 2011 Aug;77(8):835-45
pubmed: 21730932
Intensive Care Med. 1994;20(3):225-32
pubmed: 8014293
Control Clin Trials. 1984 Dec;5(4):348-61
pubmed: 6518769
Intensive Care Med. 2013 Apr;39(4):583-92
pubmed: 23370826
N Engl J Med. 2005 Oct 20;353(16):1685-93
pubmed: 16236739
Am J Respir Crit Care Med. 2001 May;163(6):1444-50
pubmed: 11371416
N Engl J Med. 1975 Feb 6;292(6):284-9
pubmed: 234174
Crit Care Med. 2006 May;34(5):1311-8
pubmed: 16557151
Am J Respir Crit Care Med. 2002 Feb 15;165(4):443-8
pubmed: 11850334
N Engl J Med. 2015 Feb 19;372(8):747-55
pubmed: 25693014
Respir Care. 2013 Sep;58(9):1416-23
pubmed: 23362167
Am J Respir Crit Care Med. 2017 Feb 15;195(4):438-442
pubmed: 27626833
JAMA. 2008 Feb 13;299(6):637-45
pubmed: 18270352
Crit Care. 2008;12(4):R91
pubmed: 18631375
Crit Care. 2007;11(4):R86
pubmed: 17688701
Crit Care. 2010;14(2):210
pubmed: 20236454
Intensive Care Med. 2006 Oct;32(10):1515-22
pubmed: 16896854
PLoS One. 2013;8(1):e53934
pubmed: 23326543

Auteurs

Kyeong Tae Kim (KT)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand. kyeong.kim@canterbury.ac.nz.

Sophie Morton (S)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Sarah Howe (S)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Yeong Shiong Chiew (YS)

School of Engineering, Monash University, Bandar Sunway, Malaysia.

Jennifer L Knopp (JL)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Paul Docherty (P)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Christopher Pretty (C)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Thomas Desaive (T)

GIGA Cardiovascular Science, University of Liege, Liege, Belgium.

Balazs Benyo (B)

Department of Control Engineering and Information, Budapest University of Technology and Economics, Budapest, Hungary.

Akos Szlavecz (A)

Department of Control Engineering and Information, Budapest University of Technology and Economics, Budapest, Hungary.

Knut Moeller (K)

Institute of Technical Medicine (ITeM), HFU Furtwangen University, Villingen-Schwenningen, Germany.

Geoffrey M Shaw (GM)

Department of Intensive Care, Christchurch Hospital, Christchurch, New Zealand.

J Geoffrey Chase (JG)

Centre for Bioengineering, University of Canterbury, Christchurch, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH